WWM
IMNM icon

Whalen Wealth Management’s Immunome IMNM Stock Holding History

Whalen Wealth Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,722
Closed -$128K – 219
2025
Q2 		$128K Buy
+13,722
New +$113K 0.08% 196

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Whalen Wealth Management's IMNM Position: Q3 2025 in Review

Whalen Wealth Management sold out of Immunome (IMNM) in Q3 2025, closing a stake of 13,722 shares — an estimated $128K sold.

Whalen Wealth Management first reported a position in IMNM in Q2 2025 and held it in 1 quarter. The position peaked at $128K in Q2 2025. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

  • Whalen Wealth Management reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
  • Whalen Wealth Management sold 13,722 Immunome shares in Q3 2025, an estimated $128K.
  • Whalen Wealth Management first reported a position in Immunome in Q2 2025 and held it in 1 quarter.
  • Whalen Wealth Management's Immunome position peaked at $128K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Whalen Wealth Management's 13F filing for Q3 2025, filed 9 Oct 2025.